bioerodible slow-release dexamethasone (dex) implant ozurdex (Allergan)
Structured Review
Bioerodible Slow Release Dexamethasone (Dex) Implant Ozurdex, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dex+implant+ozurdex/intravitreal+dexamethasone+implant+ozurdex/pm40504276-39-21-27
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Effectiveness of dexamethasone implants in treating diabetic macular edema with hard exudates: a clinical observation. Article Snippet: Eligible eyes received an intravitreal injection of the DEX implant ( Article Title: Intravitreal Dexamethasone Implant for Patients With Central Retinal Vein Occlusion: Four-Year Outcomes in a Real-World Study Article Snippet: Inclusion criteria were treatment with 0.7 mg DEX implant ( Article Title: Safety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study. Article Snippet: The commercially available DEX implant ( Article Title: Inherited retinal disease gene panel in posterior or panuveitis with dystrophic features Article Snippet: Purpose: To evaluate the presence of American College of Medical Genetics and Genomics class 3, 4, and 5 genetic variants in inherited retinal disease (IRD) genes in posterior or panuveitis with dystrophic features (PUD) in a Belgian cohort.. Methods: Multicentric, retrospective study of PUD cases diagnosed between January 2012 and February 2022.. Inherited retinal disease gene panels were analyzed in every patient. Article Title: Pseudophakic macular edema in nondiabetic and diabetic patients without diabetic retinopathy treated with intravitreal dexamethasone implant Article Snippet: Article Title: Innovative Strategies for Drug Delivery to the Ocular Posterior Segment. Article Snippet: The DEX implant ( Injection:Article Title: Efficacy of dexamethasone implant in the management of chronic central serous chorioretinopathy without choroidal neovascularization Article Snippet: .. An intravitreal injection of 0.7 mg of Article Title: A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes. Article Snippet: Objective: To compare the rates of complications in eyes that received a dexamethasone (DEX) implant (0.7 mg) or intravitreal triamcinolone (IVT) (2 mg) to treat postvitrectomy macular edema (ME).. Design: Retrospective, comparative, case series.. Subjects: A total of 148 eyes (147 patients); 75 eyes (75 patients) in the DEX group and 73 eyes (72 patients) in the IVT group. |
